Free Trial

NexgenRx Q4 2023 Earnings Report

C$0.25 -0.01 (-3.85%)
(As of 12/16/2024)

NexgenRx EPS Results

Actual EPS
-C$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

NexgenRx Revenue Results

Actual Revenue
$3.57 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NexgenRx Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>

NexgenRx Earnings Headlines

⭕ [URGENT] Buy Alert just triggered
My absolute favorite stock just hit a critical "buy now" trigger price.
NexgenRX Inc.
Closing Bell: Nexgenrx Inc up on Monday (NXG)
See More NexgenRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NexgenRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NexgenRx and other key companies, straight to your email.

About NexgenRx

NexgenRx (CVE:NXG) administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. It offers NexSys claims management; NexAdmin plan administration; and NexPSPAssist patient support programs. NexgenRx Inc. was incorporated in 2003 and is headquartered in Toronto, Canada.

View NexgenRx Profile

More Earnings Resources from MarketBeat

Upcoming Earnings